

# Jennifer L Crombie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8830258/publications.pdf>

Version: 2024-02-01

35  
papers

911  
citations

623699

14  
h-index

477281

29  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1627  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10. | 1.2  | 7         |
| 2  | Monotypic plasmacytoid cells mimicking lymph node malignancy in the setting of COVID-19 recovery. <i>American Journal of Hematology</i> , 2022, 97, 666-667.   | 4.1  | 4         |
| 3  | A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .  | 4.1  | 3         |
| 4  | The treatment of Burkitt lymphoma in adults. <i>Blood</i> , 2021, 137, 743-750.  | 1.4  | 45        |
| 5  | The future of antibody therapy in chronic lymphocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 323-336.   | 2.4  | 2         |
| 6  | Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. <i>Blood Advances</i> , 2021, 5, 3062-3065.   | 5.2  | 20        |
| 7  | Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 3563-3567.   | 5.2  | 5         |
| 8  | Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1391-1402.  | 10.7 | 53        |
| 9  | Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 115-125.   | 1.5  | 7         |
| 10 | Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm. <i>Journal of Clinical Oncology</i> , 2020, 38, 3565-3574.   | 1.6  | 16        |
| 11 | Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.  | 5.2  | 40        |
| 12 | PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 122-126.  | 5.2  | 46        |
| 13 | Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. <i>Blood</i> , 2020, 136, 46-47.  | 1.4  | 13        |
| 14 | Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 20-21.                                       | 1.4  | 16        |
| 15 | Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.   | 1.4  | 4         |
| 16 | Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020, 136, 37-38.   | 1.4  | 1         |
| 17 | Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , the, 2019, 6, e419-e428.           | 4.6  | 60        |
| 18 | Advances in drug-based therapies in chronic lymphocytic leukemia and future prospects. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e51.  | 0.9  | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. <i>Blood</i> , 2019, 134, 860-866.  | 1.4 | 178       |
| 20 | Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 575-585.   | 2.2 | 14        |
| 21 | PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.   | 1.4 | 129       |
| 22 | Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders. <i>Frontiers in Oncology</i> , 2019, 9, 109.  | 2.8 | 63        |
| 23 | The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 11-21.  | 2.3 | 4         |
| 24 | Are We Ready to Treat Diffuse Large B-Cell and High-Grade Lymphoma According to Major Genetic Subtypes?. <i>HemaSphere</i> , 2019, 3, e284.  | 2.7 | 9         |
| 25 | Current considerations in AYA Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 72-81.  | 2.5 | 20        |
| 26 | Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. <i>Blood</i> , 2019, 133, 566-575.  | 1.4 | 44        |
| 27 | A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. <i>Blood</i> , 2019, 134, 1763-1763.  | 1.4 | 6         |
| 28 | Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 32-32.                                    | 1.4 | 28        |
| 29 | Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. <i>PLoS ONE</i> , 2018, 13, e0199708.   | 2.5 | 4         |
| 30 | Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145. | 1.4 | 5         |
| 31 | PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 1650-1650.   | 1.4 | 2         |
| 32 | PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 706-706.   | 1.4 | 3         |
| 33 | Venetoclax for the treatment of patients with chronic lymphocytic leukemia. <i>Future Oncology</i> , 2017, 13, 1223-1232.  | 2.4 | 7         |
| 34 | IGHV mutational status testing in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 1393-1397.   | 4.1 | 47        |
| 35 | Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 113-118.  | 2.0 | 6         |